Mabqi is committed to delivering 100% human functional antibody leads for various therapeutic applications and areas such as oncology, neuroscience, autoimmune and inflammatory diseases, …
Based on a biological target, preclinical and clinical development requirements, Mabqi delivers readlily developable and functional human antibodies leads.
We support antibody discovery campaigns based on your targets of interest or maturation campaigns on parental hits or leads.
By partnering with us, you’ll leverage state-of-the-art capabilities that streamline your antibody discovery journey from initial concept to validated therapeutic potential.
Our expert team provides comprehensive solutions for antibody discovery and development programs, delivering seamless support across the entire discovery workflow:
Our antibody discovery platform delivers fully human antibody hits with
Unlock the power of our cutting-edge phage display libraries combined to yeast display technology to advance your antibody discovery process for virtually any targets including ion channels, GPCRs, peptides, proteins, peptide-MHC complexes, …
Our streamlined approach can deliver results in 3 months, guiding our partner through these key phases:
We can further support our clients following hits’ selection and reformatting to IgG, BsAb, ADC format, with additional in-depth profiling of antibodies, such as additional antibody characterization and investigation of functional properties.
Additional characterization is performed on antibodies (IgG, scFv, Fab, multispecific , bispecific, T cell engager, other formats, …) after a small-scale production to further identify lead candidates with desired affinity, dissociation kinetics, binding epitopes, and critical quality features.
IgGs real-time affinity ranking by BLI
Functional tests are then performed in vitro to select the best hits candidates to move towards lead selection.
A comprehensive set of standard assays will be performed on the hits to identify any potential drawbacks or limitations associated with the antibodies, ensuring their suitability for further development and application.
Diverse, developable and high-quality hits carrying unique sequences are delivered for further testing.
Based on its state-of-the-art platform, Mabqi’ discovery team performs several in vitro functional assays to select the best antibody lead candidates for further in vitro and in vivo preclinical testing.
Antibody internalization assays are crucial for developing effective antibody-drug conjugates (ADCs) and other therapeutic antibodies. These assays help identify antibodies that can efficiently enter target cells, which is essential for their therapeutic efficacy depending on initial requirements.
For 24 hours, real-time IgG internalization assays are performed with the Incucyte® integrated solution:
To evaluate antibodies targeting cell surface membrane proteins and assess their effectiveness in inhibiting cancer cell growth and survival (naked antibodies, naked antibodies with secondary cytotoxic payload antibody, ADC), two assays can be performed:
Determination of the number of living cells in culture by quantifying ATP, by CellTiter Glo® 2.0 luminescent cell viability assay.
Assays are performed with the Incucyte®, real-time, robust live-cell imaging and analysis to evaluate cell proliferation & viability.
Together, let’s innovate to improve lives and advance human health!
For questions about accessing our antibody display platform, leveraging our discovery programs, or discussing strategic partnerships, please contact us.
